NICE (UK): Aficamten can be used as an option to treat symptomatic obstructive hypertrophic cardiomyopathy in adults with a New York Heart Association class of 2 to 3…. read more.
PharmaMar announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) for the maintenance treatment for adult patients with… read more.
The European Medicines Agency’s (EMA) key human medicines committee (CHMP) has recommended twelve medicines for approval at its July 2026 meeting. This brings to 54 the number of… read more.
Cytokinetics, Incorporated announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted MYQORZO (aficamten) a marketing authorisation across the United Kingdom for the treatment of symptomatic… read more.
AbbVie announced that the European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C viru infection in adults and… read more.
Pfizer and BioNTech SE announced that the European Commission has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to… read more.
The European Medicines Agency (EMA) has begun an accelerated assessment of a potential new treatment for metastatic pancreatic cancer. Noting that pancreatic cancer is an area of high… read more.
AstraZeneca’s Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union for the treatment of adult… read more.
NICE (UK): Cemiplimab can be used as an option to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults if: i)… read more.
The European Medicines Agency (EMA) has unveiled a series of initiatives designed to address low representation of women in clinical trials and gaps in understanding sex-based differences in… read more.
Teleflex Incorporated announced it has received Biologics License Application (BLA) approval for Ezplaz Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). Ezplaz FDP is… read more.
Incyte announced that the EC has approved Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
